tak-677
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Beta-3 adrenergic receptorAGONIST
ADRB3 agonist
Discontinueddue to lack of efficacy (http://business.highbeam.com/436989/article-1G1-108457473/rafabegron-dainippon-takeda-Discontinuedeurope-usa)
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(Cl)c1- Mol. weight
- 402.88 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL279260 ↗
Also known as
- ((3-((2r)-(((2r)-3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1h-indol-7-yloxy)acetic acid
- (3-((2r)-(((2r)-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1h-indol-7-yloxy)acetic acid
- 3-cp-2-he-api-aa
- ad-9677
- ad-9677
- aj9677
- aj 9677
- aj-9677
- aj-9677
- aj-9677
- rafabegron
- rafabegron
- tak-677
- tak-677
- tak-677